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I. INTRODUCTION 
Highly active antiretroviral therapy (HAART) has significantly reduced mortality of human immuno-
deficiency virus (HIV) disease [10]. However, it is now evident, that prolonged therapy, maintaining sup-
pression of plasma viremia is not likely to eradicate HIV infection [34,82], which is why life-long therapy 
is necessary for most HIV-infected patients. A life-long treatment with HAART may lead to a broad spec-
trum of significant toxicities [4,32,43]. In addition, as a consequence of toxicity and the requirement for 
long-term daily medications, adherence to drug regimens is difficult, which can lead to the selection of 
resistant viral strains [96,18]. In an attempt to reduce the requirement for life-long therapy, several ap-
proaches to treatment interruption have been studied with patients who have maintained suppression of 
plasma viremia and relatively high CD4 cell counts while receiving HAART [25].  
Structured treatment interruption (STI) is one option that has been studied thus far. STI is investigated 
in clinical trials for several reasons: to test whether protective immune responses can be induced, to limit 
drug exposure in order to minimize toxicity and to test whether response to salvage regimens in patients 
with multiple treatment failure can be increased [29]. Our approach has been to evaluate the possibility if 
treatment interruption could be a strategy for HIV-infected paediatric patients, whose life-long treatment 
is of great difficulty. 
 
1. General information about HIV-Treatment 
1.1 Historical notes 
Zidovudine (azidothymidine, AZT) was the first antiretroviral agent licensed for AIDS in 1987 [51]. 
With the advent of AZT monotherapy the frequency of opportunistic infection was reduced and survival 
increased. The immune function in terms of the number of CD4-T-helper cells increased [75]. However, 
the drug does not prevent the progression from HIV seropositivity to AIDS or the neurological disease, 
when used in symptom-free HIV-infected people [13,5] and the beneficial effects in patients with AIDS 
wanes after about one year.  
In 1992 and 1994 didanosine (ddI) and zalcitabine (ddC), two new nucleoside analogues, were li-
censed [15,14]. At the end of 1994 it became evident, that by using a combination of two nucleoside ana-
logues applied at a low symptomatic or even symptom-free state, a better long-term effect can be 
achieved [21,40]. At the same time it became possible to quantify the antiviral effect of antiretroviral 
therapy and to compare the clinical effect with the intensity of the biologic effect [72]. Since the first 
treatment combinations that were used showed a reduction of the viral load (VL) of approximately 0.8 to 
1 log10 copies/ml (compared to 0.3 to 0.5 log10 copies/ml for the first nucleoside monotherapies), there 
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were new hopes of stronger antiviral effects of other nucleoside combinations (a reduction of 1 to 1.5 
log10 copies/ml) [54,92]. The introduction of protease inhibitors in combination with one or two nucleo-
side analogues led to permanent reductions of the viral load of 2 to 3 log10 copies/ml [41]. Since the be-
ginning of 1996 the clinical benefit of some combination therapies became evident with a spectacular 
reduction of the risk of AIDS and mortality [64]. However, antiretroviral multitherapy is limited by the 
facts that antiretroviral agents do not eliminate the virus, that there is an important risk of development of 
drug resistance and that the long-term use of antiretroviral drugs still causes relevant toxicity [95]. 
1.2 Drug classes 
Until today there are three groups of different drugs, 17 substances altogether [15]. Two classes of 
drugs work by interacting with the reverse transcriptase before the integration of the viral genes into the 
cellular DNA. The third group of drugs are protease inhibitors, interacting at the last stage of the virus 
reproduction cycle before the formation of viral particles [15,104]. Combination of drugs of these classes 
resulted in marked reductions of viral load and increase of CD4 cells. 
1.2.1 Nucleoside Analogues (NRTI) 
After an intracellular triple phosphorylation the nucleoside analogues inhibit the reverse transcriptase 
(RT) by competing with natural nucleosides. They then inhibit the prolongation of proviral DNA by inter-
rupting to link with the next nucleoside through a 3’5’-phosphodiester. At the moment only six NRTIs are 
available for paediatric use: zidovudine, lamivudine, didanosine, stavudine, zalcitabine and abacavir. 
Pharmaceutical profiles and tolerances for children are very close to those observed in adults. Only the 
pharmacokinetics of zidovudine and lamivudine have been studied closely for new born children 
[5,15,104]. 
1.2.2 Non-Nucleoside Analogues (NNRTI) 
Non-Nucleoside Analogues also inhibit the reverse transcriptase but without the necessity of being 
phosphorylated. Three molecules are licensed for adults but only efavirenz and nevirapine have been li-
censed and explored for children yet. They work selectively for HIV-1 but not for HIV-2 and an extreme-
ly quick appearance of resistant mutations during a monotherapy is known. Their strongest adverse ef-
fects are skin rash or even a Stevens-Johnson Syndrome. The incidence of hepatitis has increased with the 
use of nevirapine. Efavirenz may have adverse effects on the central nervous system [5,15 ,104]. 
1.2.3 Protease inhibitors (PI) 
The viral protease splits the precursor polyproteins of the structure proteins and the viral enzymes. It 
interferes at a late stage of the viral cycle, when the virus is being assembled. Protease inhibitors therefore 
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act on chronically infected cells. As long as the protease inhibitor is effective, the infected cell produces a 
non infectious virus. Seven protease inhibitors are already commercialized or soon to be. There are im-
portant acute and long-term adverse effects and interactions of protease inhibitors with other drugs (gas-
trointestinal effects, lipodystrophy syndrome, insulin resistance) and the taste and form of application is 
very inconvenient, especially for children [5,15 ,104]. 
1.3 Treatment guidelines 
The major goal of HIV therapy is to maintain the long-term health of the patient while avoiding drug-
related toxicity and preserving viable future treatment options [46]. With the advent of combination ther-
apy a profound and durable reduction of viral replication became achievable [22]. According to the guide-
lines for the use of antiretrovirals treatment should be offered to all patients with the acute HIV syn-
drome, those within 6 months of HIV seroconversion, and all patients with symptoms related to HIV in-
fection. Biological and immunological factors hugely influence the recommendations for offering antiret-
roviral therapy in asymptomatic patients. In that case, antiretroviral therapy should be prescribed to indi-
viduals with fewer than 15 % CD4 T-cells or plasma HIV RNA levels exceeding 100,000 cop-
ies/ml [104].  
Due to a better function of the thymus, the extent of immunological response of children to antiretrovi-
ral treatment is supposedly better than that of adults, but there is no comparison yet in studies using the 
same methods [67]. All children of HIV-infected mothers usually receive a zidovudine prophylaxis for six 
weeks with 2 mg/kg every six hours starting 12 hours after birth. In addition, a trimethoprim/sulfametho-
xazol prophylaxis (TMP/SMX) is given to all HIV-infected children during the first year of life to prevent 
the occurrence of a pneumocystis carinii pneumonia. In some countries (for example USA), a TMP/SMX 
prophylaxis is systematically given to all infants of HIV-infected mothers during the first four months of 
life, until a HIV infection can definitely be excluded [20]. 
 
Table 1: Indications for initiation of antiretroviral therapy in children < 12 months of age with 
HIV infection [104]: 
clinical category  CD4 cell count plasma HIV RNA recommendation 
symptomatic 
(clinical category A, 
B or C)* 
or < 25 % 
(immune category 2 or 3) 
any value treat 
asymptomatic 
(clinical category N)* 
and > 25 % 
(immune category 1) 
any value  consider treatment 
*according to the CDC Atlanta Paediatric Classification System 
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Concerning the benefits and risks of the use of antiretroviral agents in infants under 12 months, there 
are great therapeutical difficulties, due to a shortage of information on pharmacokinetic effects and toler-
ance of antiretroviral agents, especially of PIs over short- or long-term [20]. Since HIV infection pro-
gresses more rapidly in infants than in older children or adults, some experts would treat all HIV-infected 
infants under six months or under 12 months of age, regardless of clinical, immunological or virological 
parameters [104]. Early administration of antiretroviral treatment in the acute phase of HIV-infection 
leads to a reduction of viral load in the newborn before the irreversible damage of the immune system and 
therefore ideally leads to a maintenance of the CD4 cell reservoir. Apart from that, an early treatment 
keeps the virus from its dissemination. Because of the importance of the initial viral load for the disease 
progression, it is one of the aims of early treatment to achieve a better long-term prognosis by initially 
lowering the viral load [17,20]. 
 
Table 2: Indications for initiation of antiretroviral therapy in children > 1 year of age infected 
with HIV [104]: 
clinical category  CD4 cell count  plasma HIV RNA recommendation 
AIDS 
(clinical category C)* 
or < 15 % 
(immune category 3)
 any value treat 
mild-moderate symptoms 
(clinical category A or B)* 
or 15 - 25 % 
(immune category 2)
or > 100,000  
copies/ml 
consider treatment 
asymptomatic 
(clinical category N)* 
and > 25 %  
(immune category 1)
and < 100,000  
copies/ml 
Many experts would 
defer therapy and 
closely monitor clini-
cal, immune and viral 
parameters. 
*according to the CDC Atlanta Paediatric Classification System 
 
The first treatment prescribed after the prophylaxis is often the classic combination of two NRTIs + 
one PI or two NRTIs + one NNRTI. Combinations including NNRTIs should only be given to children 
who are considered to have a good compliance because of a rapid development of resistances against that 
group of antiretrovirals. Furthermore, it has to be determined which situations allow a treatment interrup-
tion for a short while without risking serious morbidity, and which limit of immunodeficiency can be 
tolerated without risking the quality and duration of immunological reconstitution. All recommendations 
given are therefore limited and open to further improvement [7,11,38]. 
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1.4 Toxicity 
Side-effects that appear in children taking antiretroviral drugs are: allergic reactions (nevirapine, 
efavirenz), gastro-intestinal effects (didanosine), nephrolithiasis (indinavir) and neurological effects (efa-
virenz). Hepatocellular insufficiency that can appear after taking nevirapine has not yet been reported in 
children, whereas mitochondrial toxicity has been seen in children as well as lipodystrophy. Neither the 
incidence of lipodystrophy in children nor its long-term effect on the cardiovascular system have been 
fully explored yet [50]. 
1.4.1 Lipodystrophy syndrome 
This syndrome is characterized by body fat redistribution leading to peripheral fat wasting and central 
obesity with accumulation of visceral fat and enlargement of the breast and neck (“buffalo neck”) [9]. 
Metabolic abnormalities have also been reported, such as elevated triglyceride and cholesterol levels, and 
insulin resistance or type 2 diabetes mellitus [80]. Lipodystrophy and specifically the loss of subcutane-
ous fat (lipoatrophy) is a significant and distressing side-effect of antiretroviral therapy [8]. Multiple sur-
veys have shown that clinical factors such as age, the CD4 cell count, and others are important predispos-
ing factors. Some observational studies have found an association between lipodystrophy and either com-
plete viral suppression, a history of a low CD4 cell count or, in particular, the change in CD4 cell count 
during therapy [79]. The role of protease inhibitors and nucleoside reverse transcriptase inhibitors (NRTI) 
in the occurrence of lipodystrophy has been investigated in different studies [61,44,94,70]. The exact 
mechanisms with which PIs [102,81,55] and NRTIs [12,98,59,52,78] contribute to this syndrome has yet 
to be evaluated. Although the initial identification of this syndrome was coincident with the widespread 
use of PI-containing regimens, more recent reports have concluded that it may also occur in the absence 
of PIs [68,93]. 
There are several possible sequelae of lipodystrophy syndrome. Firstly, adherence to antiretroviral 
therapy could be compromised because of cosmetic effects, leading to virological and even clinical failure 
[60,65]. Secondly, the metabolic effects can lead to an increase in cardiovascular disease [23], and several 
case reports have described premature coronary-artery disease in patients with few or no risk factors that 
were receiving protease inhibitor therapy [45,31]. Increased exercise can decrease central fat accumula-
tion but at the expense of increased peripheral fat wasting [77].  
1.4.2 Mitochondrial toxicity 
One of the major toxicities of NRTI therapy, particularly over medium-term to long-term, is thought to 
be secondary to inhibition of mitochondrial DNA polymerase γ, resulting in impaired synthesis of mito-
chondrial enzymes that generate ATP by oxidative phosphorylation. These include myopathy (zidovudi-
ne), neuropathy (stavudine, didanosine, zalcitabine), hepatic steatosis and lactic acidaemia (didanosine, 
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stavudine, zidovudine) and possibly also peripheral lipoatrophy (possibly all NRTIs, although predomi-
nantly with stavudine) and pancreatitis (didanosine) [9,6]. The most serious mitochondrial toxicities are 
lactic acidosis and pancreatitis.  
The management of mitochondrial toxicity is generally limited to cessation of the causative drug and 
sometimes of other drugs that might exacerbate the condition. Some toxic effects, such as peripheral neu-
ropathy, may worsen for several weeks after drug cessation (“coasting phenomenon”). Several agents 
have been used in the treatment of congenital mitochondrial diseases with limited success [9,89]. These 
agents include essential vitamin coenzymes (thiamine and riboflavin), electron acceptors (vitamin C), an-
tioxidants (compound Q), and L-carnitine. Patients with zidovudine-induced myopathy and NRTI-indu-
ced peripheral neuropathy have been shown to have reduced concentrations of L-carnitine [9]. 
1.4.3 Allergic reaction 
Allergic reactions in HIV-1-infected patients are about 100 times more common than in the general 
population. An allergic reaction typically manifests as an erythematous, maculopapular, pruritic and con-
fluent rash with or without fever beginning after one to three weeks of therapy. All licensed NNRTIs 
(nevirapine, delavirdine, efavirenz), the NRTI abacavir (hypersensitivity) and the PI amprenavir are com-
mon antiretroviral drugs that cause allergic reactions, which is rare in other NRTIs or PIs [9]. 
The pathogenesis of such allergic reactions is unknown. Suggested causes and mechanisms include the 
degree of immunodeficiency or immune activation, the longer duration and higher doses of therapy, al-
tered drug metabolism associated with gluthation deficiency or slow acetylator phenotype and co-
infections with cytomegalovirus and Epstein-Barr virus [9]. Recent studies have shown a potential genetic 
predisposition for a hypersensitivity reaction to abacavir [47]. Two different teams of investigators have 
identified a strong association between a rare HLA type and the risk of developing abacavir hypersensi-
tivity [30,69]. About 50 % of antiretroviral allergic reactions resolve spontaneously despite continuation 
of therapy. Therapy should be stopped if there is mucosal involvement, blistering, exfoliation, clinically 
significant hepatic dysfunction, fever greater than 39°C or pruritus [9]. Desensitisation is unstudied for 
NRTIs and may be inappropriate for antiretroviral allergic reactions and abacavir hypersensitivity, since it 
would necessitate a period of subtherapeutical drug concentration and so favour development of drug 
resistance [9]. 
1.5 Resistance to antiretroviral therapy 
Viral resistance is an important problem for the treatment of HIV-infected patients and probably the 
strongest limit. Even though the mortality rate in HIV-infected children has decreased to almost zero in 
the last two or three years in industrialised countries, the majority of European and American studies note 
an insufficient suppression of viral replication until today, which is stronger in children than in adults 
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[17,20,101]. A large number of children stay clinically asymptomatic without any sign of immunodefi-
ciency, but have a persisting viral replication, which, even if existing at a low level, can easily lead to the 
emergence of resistant viral strains. One of the main reasons for that is probably the difficulty of adher-
ence to a combination therapy [101,88,3], which is mainly due to adverse effects, toxicity or the fact that 
sometimes numerous pills have to be taken a day, which can be disturbing in everyday life [104,39].  
The selection of resistant viral strains, due to growing selection of mutations under subtherapeutical 
levels, can have a durable influence on the efficiency of a treatment, also because cross-resistance be-
tween substances of the same drug family is widespread. Especially resistance against NNRTIs appears 
rapidly and is difficult to burn out, so that it is strongly advised to carry out resistance-testing before 
every start of a new treatment [37]. 
However, resistance and insufficiency may not only be caused by a subtherapeutical dosage of antiret-
roviral treatment but also by a potentially different replication profile of the virus in children. Even 
though the development of resistant virus strains has not yet been fully explored in children, it is probably 
the major reason for a remaining viral replication during antiretroviral treatment [104,101]. 
1.6 Structured treatment interruption (STI) 
A few years ago, treatment interruption was not considered as treatment option, and patients who in-
terrupted therapy generally did so of their own will, which was described as non-adherence. “Drug holi-
days” were occasionally recommended though, for example to allow resolution of drug-toxicity, but it 
was assumed that once started, antiretroviral treatment was a life-long commitment [35]. Today antiretro-
viral treatment may be interrupted for the following reasons: 
• Request for treatment interruption by the patient, 
• carelessness/non-observance, 
• adverse effects/toxicity, 
• change of treatment guidelines [57]. 
For four or five years now, the strategy of structured treatment interruption (STI) in HIV infected pa-
tients has been discussed mainly for three therapeutical reasons: (1) to stimulate the anti-HIV immune 
response after viremia has been suppressed by treatment, (2) to raise compliance by increasing time off 
therapy, improving quality of life and diminishing toxicity, and (3) in the case of the occurrence of mul-
tiresistant virus strains. In that case therapy is interrupted before starting a salvage therapy in the hope of 
achieving a resusceptibility of the virus to different available antiretroviral agents [103,63,100]. By inter-
rupting HAART and later restarting all antiretroviral agents simultaneously, the development of drug 
resistance can be reduced to a minimum. 
STI is especially considered for those patients for whom other treatment options are no longer success-
ful or even harmful and can only be carried out on the strict condition that both viral load and CD4 cells 
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are regularly checked. Immunological and clinical consequences of treatment interruption vary in every 
patient [57]. Each HIV-infected person has to be regarded individually and their medical history must be 
closely examined (CD4 cell counts should not have decreased below 300-350/mm3) before deciding to-
gether with the patient and care-giver whether a treatment interruption is useful [74]. Unfortunately, with 
the exception of some reports of sustained suppression, fairly prompt virological relapse and the occur-
rence of AIDS events after discontinuation of antiretroviral treatment has been the predominant pattern 
observed thus far in clinical trials [36,62,84,42]. Along with a rapid increase of viral load a brisk decrease 
of CD4 cells can be observed [16,105,49] and a lot of patients run the risk of manifesting a state that re-
sembles a primary infection so that a restart of antiretroviral treatment becomes necessary [20].  
One rationale for interrupting therapy, and one of the earliest to be studied, argues that periodic expo-
sure of the immune system to low-level viremia might stimulate HIV-specific cellular immunity. This 
appears to be retained in patients, whose disease course progresses only slowly over a long period of time, 
but is lost in the majority of chronically infected patients [53]. It was hoped that the HIV-specific immune 
response stimulated by intermittent therapy might ultimately allow the immune system to control HIV 
without the need of drug therapy. Interest in this approach was stimulated in part by reports of the famous 
“Berlin patient”, who initiated antiretroviral therapy shortly after infection and who was able to maintain 
an undetectable viral load and strong HIV-specific CD4 and cytotoxic T-lymphocyte (CTL) responses 
without antiretroviral therapy after a number of unplanned treatment interruptions [62]. Enthusiasm for 
this approach has waned, at least for chronically infected patients, due to discouraging data from clinical 
trials.  
In the ongoing Staccato study, 600 patients on successful antiretroviral treatment were to be random-
ised to either continued therapy, CD4-guided therapy, or one-week-on/one-week-off therapy. A scheduled 
preliminary analysis evaluated effectiveness in the 1-week-on-1-week-off arm. This schedule showed an 
unacceptably high failure rate and was therefore terminated. Of 36 evaluable patients, 19 (53%) had two 
successive HIV RNA concentrations > 500 copies/ml at the end of the week off therapy, and were classi-
fied as virological failure. Most of those who failed (eleven patients) took didanosine, stavudine, saqui-
navir, and ritonavir [2].  
The Swiss and Spanish Intermittent Treatment Trial (SSITT) used an eight-weeks-on/two-weeks-off 
schedule in 133 chronically infected patients who had been successfully treated with antiretroviral ther-
apy. After 52 weeks, 18 % of the patients showed their immune systems responding against HIV off ther-
apy (viral load < 5000 copies/ml). After 96 weeks, 11 % were still showing response off therapy. It was 
noted, for example, that the best results were observed in patients who had low baseline viral loads to 
begin with [48]. 
The STI strategy may especially be viable in patients treated during primary infection. A study group 
at the Massachusetts General Hospital has reported data from a select group of HIV-infected patients who 
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were diagnosed and treated before Western blot seroconversion [99]. Of 14 such patients, eight main-
tained viral loads < 5000 copies/ml after at least one STI. The results have been very promising but are 
possibly due to early initiation of treatment since they were not seen in other studies [42,83,76]. Con-
trolled trials are being planned to assess the effectiveness of STI after early antiretroviral therapy. Efforts 
to study STIs in this patient population are limited by the fact that only few patients are diagnosed during 
acute infection.  
Another rationale for interruption of therapy is to allow re-emergence of wild-type virus and thereby 
improve response to salvage therapy in heavily experienced patients with extensive drug resistance 
(Structured Intermittent Therapy = SIT). It has been clearly demonstrated that discontinuation of antiret-
roviral therapy leads to replacement of resistant virus by wild-type virus. One study group has demon-
strated that in patients who discontinue a failing HAART regimen, drug susceptibility increases at a me-
dian of six weeks after discontinuation and is associated with increases in plasma HIV-1 RNA, decreases 
in CD4 cell count, and increases in viral replicative capacity, sometimes referred to as “fitness” [19]. This 
is believed to reflect the re-emergence of the more virulent wild-type virus, replacing the mutant virus 
maintained by the selective pressure of the failing regimen [35]. Hypothetically multidrug resistant virus 
might be so unfit, that it would not persist indefinitely in the absence of therapy and would thus give pa-
tients a renewed opportunity for durable viral suppression [19].  
However, in highly experienced patients failing antiretroviral therapy, discontinuation of HAART 
prior to initiation of salvage therapy is a promising but potentially hazardous approach. While it may al-
low restoration of drug-susceptible virus, there is also a significant decline in CD4 cell count and the po-
tential for opportunistic infections or other complications of untreated HIV infection. Deeks and col-
leagues concluded from their study, that despite the presence of reduced drug susceptibility, antiretrovi-
ral-drug therapy can provide immunologic and virologic benefit. This benefit reflects continued antiviral-
drug activity and the maintenance of viral population with a reduced replicative capacity [19]. Further-
more, the virological benefit after re-initiation of therapy is expected either to be transient or to require a 
complex multidrug salvage regimen in order to maintain suppression [35]. 
The remaining treatment interruption approaches seek to decrease total time on therapy, either through 
time-based treatment cycles (SIT) or CD4 cell count based cycles (“pulse therapy”). The idea of pulse 
therapy is to keep the CD4 cell count above a predetermined threshold using cycles of therapy followed 
by prolonged interruptions. There are two studies supporting an approach for pulse therapy: a study from 
Argentina [58] and an observational cohort study at Johns Hopkins University [87]. There may be a sub-
set of patients, presumably those with relatively low viral load set points and good CD4 cell count re-
sponses to HAART, who will be able to discontinue therapy safely for prolonged periods of time [35].  
Regarding antiretroviral therapy and its consequences in adults, including new strategies to enforce the 
fight against HIV, it is important to find out, whether children can profit from similar strategies. Although 
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viral resistance, adverse-effects and risks of treatment interruption are already documented in different 
studies for adults, no data address them in children yet. With this pilot study we retrospectively evaluated 
the effects of treatment withdrawal in HIV-infected children in order to prepare a prospective study. 
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II. PATIENTS AND METHODS 
1. Study population 
We studied all HIV-1 infected children that attended the Paediatric Clinic of Haematology and Immu-
nology at the Hôpital Necker-Enfants Malades in Paris, France, who had received antiretroviral treatment 
for at least ten months, before stopping therapy completely for an individual length of time between 1996 
and 2000. Altogether, 300 children are treated for their HIV infection at Necker-Enfants Malades, 250 of 
which receive antiretroviral treatment. We had a study population of 35 eligible paediatric patients who 
were under medical treatment in that hospital. In a retrospective study we observed this group concerning 
their discontinuation of antiretroviral therapy after months or years of receiving treatment.   
 
2. Classification of the group 
The CDC Atlanta Paediatric Classification System was used to define infection status and clinical and 
immunological conditions before treatment interruption. 
 
Table 3: CDC Atlanta Paediatric Classification System [104] 
 non 
symptomatic 
mildly 
symptomatic 
moderately 
symptomatic 
severely 
symptomatic 
no 
suppression 
CD4 > 25 % 
 
N1 
 
A1 
 
B1 
 
C1 
moderate 
suppression 
CD4 =15–24 % 
 
N2 
 
A2 
 
B2 
 
C2 
severe 
suppression 
CD4 < 15 % 
 
N3 
 
A3 
 
B3 
 
C3 
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Table 4: Clinical categories of the CDC Atlanta Paediatric Classification System [104] 
category symptoms 
 
 
A 
lymphadenopathy 
hepatomegaly 
splenomegaly 
parotitis 
dermatitis 
 
 
 
B 
anaemia 
candidiasis 
cardiomyopathy 
CMV 
hepatitis 
LIP (lymphoid interstitial pneumonia) 
nephropathy 
 
C 
 
Children, who have any condition listed in the 
1987 surveillance case definition for acquired immu-
nodeficiency syndrome, with the exception of LIP 
(which is a category B condition). 
 
Immunological parameter (HIV RNA viral load and CD4 T-lymphocyte count) were collected every 
three months and recorded in addition to other information about every child in special forms, including:  
• name,  
• age,  
• type of contamination,  
• date and reason for treatment interruption,  
• medical history of viral load and CD4 T-cell count (noted were the highest plasma HIV RNA 
count and the lowest CD4 T-lymphocyte count ever detected during antiretroviral therapy).  
 
3. Treatment 
Antiretroviral therapy was prescribed individually for each child on the basis of guidelines for the use 
of antiretroviral agents in HIV-infected children and adolescents and was adopted to the child’s weight, 
age and unique therapeutical and management considerations. Most of the children received a zidovudine 
prophylaxis for six weeks after birth. Few children had not been followed up from birth and therefore had 
not received any prophylaxis. As soon as their seropositivity was discovered, they received either zido-
 17
vudine or lamivudine monotherapy adopted to their current weight. If clinical symptoms had already ap-
peared, the children initially received combination therapy. 
We recorded all regimens received until the day of treatment interruption including:  
• dosage,  
• reasons for changing dosage,  
• route of administration,  
• adverse effects,  
• start and type of the first antiretroviral therapy ever received, 
• reason for changing therapy, date of onset and combination of new treatment, 
• clinical effects appearing after discontinuing therapy,  
• reason for restarting therapy, date of onset and combination of new treatment. 
We subdivided the range of treatment regimens into three different groups. (1) children that received a 
bitherapy, consisting of two NRTIs, (2) those who took therapies including PIs, no matter how many 
drugs were used altogether, (3) those who took a therapy other than those two listed above. No child re-
ceived a monotherapy by the time antiretroviral therapy was interrupted.  
 
4. Treatment interruption 
Antiretroviral combination therapy was stopped either by the consulting doctor, the child’s care-givers 
or the child itself in the time between January 1996 and December 2000. We classified all children into 
three groups according to the following reasons of their treatment interruption: 
• toxicity (n=11), 
• inefficiency (n=17), 
• inconvenience (n=7). 
4.1 Adverse effects and toxicity 
For eleven children (31.4 %) treatment interruption was decided for reasons of severe adverse-effects 
and toxicity. Common intolerances to drugs were caused by indinavir, ritonavir, nelfinavir, and efavirenz. 
Side-effects that often occurred were hepatic toxicity such as cholestase (n=3) and hepatitis, especially 
when taking PIs and repetitive skin rash appeared after intake of NNRTIs (n=4). Gastro-intestinal effects, 
such as nausea (n=5), intractable vomiting (n=2) and chronic diarrhoea (n=3) were usually caused by 
NRTIs but also after taking nelfinavir. Nephrolithiasis caused by an incompatibility to indinavir was also 
a common adverse-effect (n=5). One child though had to stop therapy because of a severe lipodystrophy 
syndrome she developed after taking a combination therapy that included nelfinavir for eleven months. 
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4.2 Inefficiency 
17 children (48.6 %) stopped antiretroviral therapy for reasons of virological failure. They were in a 
good clinical state and remained asymptomatic without any sign of immunodeficiency. However, viral 
replication persisted on a high level and could not be successfully suppressed mostly because of the oc-
currence of multiresistance but also because of non-adherence to the treatment. In such cases it was de-
cided to change antiretroviral therapy to a more successful combination therapy. However, rapid changes 
of combination therapy risk a limitation to future treatment options, especially in long-term HIV therapy. 
Consequently, treatment was interrupted to burn out resistance and to possibly achieve a change back to 
the “wild type” virus. Three asymptomatic children, whose viral load and CD4 cells stayed in a steady 
state stopped treatment since they did not need further therapy for the moment and were also grouped into 
the category “inefficiency”. 
4.3 Inconvenience 
The third reason for treatment interruption was inconvenience and applied to seven children (20 %). 
This category includes lack of adherence and the child’s or care-givers’ decision to stop therapy for rea-
sons of incompatibility, inability to swallow or simply carelessness. This was often the case, when parents 
suffered from severe HIV infections themselves and were hospitalised, so that an orderly care for the 
child, including regular treatment administration was not evident. Older children who had reached the age 
of puberty and took antiretroviral therapy independently, stopped medication themselves. Often they 
found an antiretroviral treatment too uncomfortable or embarrassing even in terms of outing themselves 
in public. 
 
5. Immunological and virological tests 
Plasma HIV RNA was tested approximately every three months. The average time between the last 
plasma HIV RNA test during antiretroviral treatment and the first during treatment interruption was 118 ± 
65 days. Amplicor HIV-1 Monitor RNA polymerase chain reaction (PCR) test (Roche Diagnostics, 
Branchburg, NJ) was used to quantify plasma HIV RNA concentrations. PCR is a very sensitive method 
that measures the presence or amount of RNA or DNA of a specific organism or virus (for example: HIV) 
in the blood or tissue [71]. The Amplicor RNA PCR test is a highly sensitive test, proven to detect viral 
loads as low as 50 RNA copies per ml [90].  
The CD4 cell count was regularly checked approximately at the same time as the viral load (every 
three months). The average time between the last CD4 cell count before treatment interruption and the 
first CD4 cell count during treatment interruption was 121 ± 66 days. The CD4 and CD8 T-lymphocyte 
count was measured by flow cytometry and noted in both absolute numbers and percentages. Flow cy-
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tometry uses fluorescent antibodies to detect IgG or IgM antibodies bound to autologous or allogenic 
cells. It is used to measure cell size, number, viability, and nucleic acid content [71]. 
 
6. Resistance testing 
To estimate the presence of major mutations in the HIV reverse transcriptase and protease genes, 
genotypic resistance was tested before treatment interruption at a time when the child was still under anti-
retroviral therapy. In order to detect new resistance development or the decline of former gene mutations 
and drug resistance, tests were carried out regularly in the absence of antiretroviral treatment. Finally, an-
other test was run in the case of a restart of therapy, when a new combination of efficient agents had to be 
defined for the child.  
 
7. Restart of therapy 
Antiretroviral therapy was resumed whenever CD4 cell counts declined to less than 15 % or viral load 
was continuously detected above 5 log10 copies/ml. As soon as severe clinical symptoms appeared, ther-
apy was restarted, even if immunological parameters had not yet reached such dangerous levels. In two 
cases the child itself or the child’s care-givers elected to resume drug treatment independent of these 
thresholds. 
 
8. Analysis 
In order to evaluate the data for CD4 cell changes after treatment interruption, the analysis is based on 
the following equations. CD4 X0 is defined as the baseline. The baseline is the last CD4 cell count before 
treatment interruption, measured at day t0. CD4 X1 was the first CD4 cell count measured after treatment 
interruption at day t1 (CD4 cells were noted in % of white blood cells). 
Therefore, ∆CD4 is: 
)01(
04144
tt
XCDXCDCD −
−=∆   
 
This equation shows the percentage of lost or gained CD4 cells per day of treatment interruption.  
This way, we calculated the average CD4 cell loss during treatment interruption. The average CD4 
cell loss can be more or less severe, depending on how high or low the patient’s CD4 cell baseline was. 
Therefore, the baseline was also included into the equation. 
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Subsequently, ∆’CD4 describes the loss or gain of CD4 cells per day of treatment interruption accord-
ing to the individual baseline. The result is therefore noted in % of the individual baseline of each child. 
∆’CD4 is: 
 
( ) )01/(
04
10004144' tt
XCD
XCDXCDCD −×−=∆  
 
Similar equations were used to analyse the data for viral loads. VL X0 is defined as the last viral load 
before treatment interruption at day t0, setting the baseline. If VL X1 is the first viral load detected after 
treatment interruption on day t1, ∆VL is: 
 
)01(
01
tt
VLXVLXVL −
−=∆  
 
showing the average viral load gained or lost per day of treatment interruption. Therefore ∆’VL is: 
 
( ) )01/(
0
10001' tt
VLX
VLXVLXVL −×−=∆  
 
and stands for the average gain or loss of plasma HIV RNA according to the baseline per day of treat-
ment interruption. 
Differences between categorical variables were tested in order to interpret the course of CD4 cell 
counts after treatment interruption regarding: 
• age (older or younger than five years),  
• sex, 
• reasons of treatment interruption (inefficiency versus toxicity/inconvenience), 
• medical history of viral load (more or less than 5 log10 copies/ml of HIV RNA), 
• medical history of CD4 T-cell count (more or less than 5 %). 
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We did the same analysis for the results of viral load gain or loss, concerning the same variables like: 
• age (older or younger than five years), 
• sex, 
• reason of treatment interruption, 
• medical history of viral load, 
• medical history of CD4 T-cell count. 
In all 35 HIV-1 infected children the empirical equations described above were used to interpret the 
dynamics of HIV-1 RNA and CD4 cells in the time after treatment interruption. 
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III. RESULTS 
1. Features of the study group 
Overall 35 children born to HIV-infected mothers between 1981 and 1997 were studied; 27 of these 
children (77.1 %) were prospectively followed up from birth. All children acquired HIV-infection through 
vertical transmission. 20 children are of European, 14 of African and one child is of Caribbean origin. All 
children received antiretroviral therapy for at least ten months before interrupting treatment at some point 
between 1996 and 2000. Sixteen children were born to mothers who were injecting drug users, 12 were 
born to mothers, who came from continents with a high HIV infection rate such as Africa and seven chil-
dren were born to mothers, who had acquired HIV infection through transfusions or infected sexual part-
ners. The group consisted of 16 girls and 19 boys, with the youngest patient being three years and eight 
months old and the oldest child 19 years and seven months old at study-end in December 2000.  
The average age at the time antiretroviral therapy was started was 3.5 years ± 3.8 and the median age 
2.0 years [0;15.3]. At the time, antiretroviral therapy was stopped, the average age was 10.4 years ± 4.9 
years and the median age 11.1 years [1.3;18.3]. Altogether, 29 children (82.9 %) were over five years old 
and only six (17.1 %) were under five years when antiretroviral therapy was interrupted. The average 
time, for which treatment was taken was 80.8 months ± 48.6 before withdrawal of antiretroviral therapy, 
the median time was 79 months [10;160]. The time of treatment administration mainly depended on the 
child’s age, since older children generally received antiretroviral therapy for a longer period of time.  
Regarding the patients’ clinical and immunological state before treatment interruption, a CD4 cell 
count below 5 % (at a time while the patient was receiving HAART) was defined as “a medical history of 
severe immunodeficiency”. A viral load (VL) above 5 log10 copies/ml (at a time while the patient was re-
ceiving HAART) was defined as “a medical history of severe increase of viral load”. 
 
Table 5: Medical history of immunodeficiency and severe increase of viral load 
medical history number of children 
viral load  > 5 log10 copies/ml * 10 
viral load  < 5 log10 copies/ml 25 
CD4 cell count  < 5 % ** 13 
CD4 cell count  > 5 % 22 
viral load > 5 log10 and CD4 cell count < 5 % 5 
* A VL > 5 log10 copies/ml while receiving HAART was defined as “a medical history of a severe increase of viral load”. 
** A CD4 cell count < 5 % while receiving HAART was defined as “a medical history of severe immunodeficiency”. 
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All children were classified according to the CDC Atlanta Paediatric Classification System: 
Table 6: Immunological and clinical state of the patients 
CDC Atlanta Classification System number of children 
N3 1 
A1 3 
A2 4 
A3 4 
B1 2 
B2 1 
B3 18 
C3 2 
 
Apart from one child staged N3, all children developed mild symptoms, such as lymphadenopathy, 
hepatomegaly, splenomegaly or parotitis which are classified A. Common symptoms in the group of chil-
dren classified B were candidiasis, HSV or a herpes zoster, three children developed a lymphoid intersti-
tial pneumonia (LIP). The two children categorized C had developed a malignant Non Hodgkin Lym-
phoma. 
 
2. Treatment 
21 children (60 %) in our cohort took an antiretroviral regimen that included a PI, 16 of which took a 
treatment that consisted of one PI and two NRTIs (mostly AZT + 3TC or 3TC + d4T). Four of the chil-
dren receiving PIs used a quadritherapy. 
Six children (17.1 %) had a dual combination regimen consisting of only two NRTIs in different com-
binations (such as AZT + 3TC ; AZT + ddC ; d4T + ddI ; d4T + 3TC).  
Eight children (22.9 %) took a therapy, which did not include a PI. Those were combinations of either 
two NRTIs + one NNRTI or three NRTIs. None of the children received a monotherapy by the time 
treatment was stopped. 
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Table 7: Treatment combinations 
number of agents combination number of children 
bitherapy 2 NRTI 6 
triple therapy 2 NRTI + 1 PI 
2 NRTI + 1 NNRTI 
1 NRTI + 2 PI 
3 NRTI 
16 
6 
1 
2 
quadritherapy 2 NRTI + 2 PI 
2 NRTI + 1 NNRTI + 1 PI 
1 NRTI + 1 NNRTI + 2 PI 
1 
2 
1 
 
Table 8: PIs used in treatment combinations 
PI number of children 
nelfinavir 11 
amprenavir 3 
indinavir 3 
saquinavir 2 
ritonavir 1 
lopinavir 1 
 
 
3. Treatment interruption 
3.1 Clinical course 
The average time of observation after treatment interruption was 325 ± 294 days, with a median time 
of 258 days [11;1536]. In the absence of antiretroviral treatment, three children developed slight symp-
toms like skin reactions (erythema or prurigo) or candidiasis and one child developed a herpes zoster 
infection in addition to a trichophyton infection. Another child suffered from thrombopenia and epistaxis 
and one child developed a LIP during treatment interruption, so that these two children had to restart ther-
apy. They were the only two children, who restarted therapy due to clinical events. 21 children were in a 
good state of health and still without antiretroviral therapy by the time we finished the study at the end of 
December 2000. 
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3.2 Virological and immunological course 
Viral loads increased in all children after treatment interruption, and CD4 cell counts decreased in the 
same way. However, in the course of treatment interruption, we noted three different types of virological 
and immunological reaction:  
• 14 children immediately developed a brisk increase of viral replication (above 5 log10 copies/ml) 
and a sharp decrease of CD4 cells (below 15 %). Ten of these children remained on such levels, so 
that a restart of therapy became necessary. The other four children had high viral loads but not 
constantly above 5 log10 copies/ml and their CD4 cell counts did not constantly decrease to under 
15 % so that a restart of therapy was not decided. 
• Eleven children stayed in a steady state. They had constantly low viral loads (between 3 and 4 
log10 copies/ml) or even undetectable levels, and their CD4 cell counts were always above 15 %. 
Nine of these children were still without therapy two years after treatment interruption, in two 
cases the child or the parents wished to resume therapy.  
• The last group consists of ten children, who alternated between these two variations. They were 
dealing well with the cessation of their therapy, but in contrast to the second group, they reached 
higher levels of viral load and lower CD4 cell counts from time to time, which kept them from 
maintaining a steady state. Two of these children restarted therapy because of clinical events (lym-
phoid interstitial pneumonia and thrombopenia with frequent episodes of epistaxis). The other 
eight children were still without therapy by the end of the study. 
3.2.1 Virological course 
The average time between the last plasma HIV RNA test during antiretroviral treatment and the first 
test after treatment interruption was 118 ± 65 days. During that time, the viral load increased by 0.944 ± 
1.416 log10 copies/ml, which are 0.008 ± 0.012 log10 copies/ml per day. Therefore, according to the indi-
vidual baseline, a child gained 0.2 ± 0.6 % of the baseline viral load per day of treatment interruption. 
Consequently, a child with a baseline of 10,000 copies (4 log10 copies/ml) showed an increase of viral 
load of approximately 20 copies per day of treatment interruption.  
3.2.2 Immunological course 
The average time between the last CD4 cell count directly before treatment interruption and the first 
CD4 cell count during treatment interruption was 121 ± 66 days. The average loss of CD4 cells during 
that time was 0.06 ± 0.12 % CD4 cells per day, which is 0.3 ± 0.5 % of the individual baseline. Subse-
quently, a child had lost approximately 30% of the baseline CD4 cell count by the time CD4 cells were 
first measured in the absence of therapy (after 121 ± 66 days). 
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4. Factors associated with immunological decline 
Assuming that the course of HIV RNA viral load and CD4 cell count depended on certain factors, dis-
tinctions were made between the medical history of viral load and CD4 cell count, age, sex and reason for 
treatment interruption. A ‘p’ lower than 0.05 was defined as being statistically significant. 
4.1 Associations with the decline of CD4 cell count 
In children under five years of age (n=6) a loss of 3.0 ± 3.4 % CD4 cells was observed at the first 
measurement after treatment interruption (after 121 ± 66 days), which is 0.025 ± 0.028 % per day. Chil-
dren older than five years (n=29) lost 6.9 ± 13.2 % CD4 cells (0.057 ± 0.109 % per day). Male patients 
(n=19) showed a loss of 5.1 ± 7.2 % (0.042 ± 0.059 % per day), while female children (n=16) lost 
7.6 ± 16.4 % CD4 cells during treatment interruption (0.063 ± 0.135 % per day). 
According to the different reasons for treatment interruptions, we made a distinction between those pa-
tients, who stopped therapy for reasons of inefficiency and those who discontinued for other reasons such 
as toxicity or inconvenience. Those of the first group (n=17), who interrupted therapy for reasons of low 
efficacy lost 8.7 ± 15.2 % CD4 cells (0.072 ± 0.126 % per day), while a loss of only 3.8 ± 8.2 % CD4 
cells was observed for the remaining children (n=18) that interrupted treatment for reasons of toxicity or 
inconvenience (0.031 ± 0.068 % per day). 
In addition, the association between the medical history of viral load before treatment interruption and 
the course of CD4 cells after treatment interruption was examined. The 10 children who had a medical 
history of a severe increase of viral load (> 5 log10 copies/ml) had a decline of 7.6 ± 13.9 % CD4 cells 
(0.063 ± 0.115 % per day). The 25 children who had a medical history of viral load below 5 log10 cop-
ies/ml lost 2.8 ± 4.9 % CD4 cells (0.023 ± 0.04 % per day). We also studied the association between the 
medical history of CD4 cells before treatment interruption and the course of CD4 cells after treatment 
interruption. The 13 children with a medical history of severe immunodeficiency (CD4 cell count < 5 %), 
lost 6.7 ± 13.7 % (0.055 ± 0.113 % per day) in contrast to the 22 children with a stronger immune system 
(CD4 cell count > 5 %) who lost 5.3 ± 9.6 % CD4 cells (0.044 ± 0.079 % per day).  
4.2 Associations with the increase of viral load 
For the six children under five years of age, we observed a gain of 0.354 ± 0.59 copies/ml HIV RNA 
at the first measurement after treatment interruption (0.003 ± 0.005 log10 copies/ml per day). Those above 
the age of five years showed a gain of viral load of 1.18 ± 1.416 log10 copies/ml during that time (0.010 ± 
0.012 log10 copies/ml per day). This result is statistically significant with p=0.05.  
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For the 19 male children of our cohort the viral load increased by 1.18 ± 1.298 log10 copies/ml 
(0.010 ± 0.011 log10 copies/ml per day). Female children showed an increase of 0.826 ± 1.416 log10 cop-
ies/ml (0.007 ± 0.012 log10 copies/ml per day).  
In terms of cessation of antiretroviral therapy, we distinguished between inefficiency of therapy and 
other reasons such as toxicity or inconvenience. Children, who interrupted therapy because of inefficiency 
of their present drug regimen, gained 0.944 ± 1.534 log10 copies/ml after treatment interruption (0.008 ± 
0.013 log10 copies/ml per day). The 18 children who discontinued therapy for other reasons showed a HIV 
RNA gain of 1.062 ± 1.18 log10 copies/ml (0.009 ± 0.010 log10 copies/ml per day). 
Concerning the medical history of CD4 cell count, the 13 children with a medical history of severe 
immunodeficiency (CD4 cell count < 5 %) showed an increase of HIV RNA of 0.944 ± 1.062 log10 cop-
ies/ml (0.008 ± 0.009 log10 copies/ml per day) while those patients with a CD4 cell count above 5 % 
gained 1.18 ± 1.18 log10 copies/ml (0.010 ± 0.010 log10 copies/ml per day). We also observed an associa-
tion between the medical history of viral load before treatment cessation and the course of viral load af-
terwards. This led to the result that the 10 children with a medical history of a severe increase of viral 
load gained 1.18 ± 2.36 log10 copies/ml (0.010 ± 0.02 log10 copies/ml per day). The remaining 25 chil-
dren, who had a HIV RNA of less than 5 log10 copies/ml, gained 0.59 ± 0.708 log10 copies/ml by the time 
the viral load was first measured after treatment interruption (0.005 ± 0.006 log10 copies/ml per day). 
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Table 9:  Associations with the decline of CD4 cell count and the increase of viral load (VL) 
 (at the time of the first measurement after treatment interruption) 
 
 decrease of CD4 cells in % 
(after 121 ± 66 days) 
p increase of VL in log10 copies/ml 
(after 118 ± 65 days) 
p 
medical history of viral load* 
< 5 log (copies) 
 > 5 log (copies) 
 
-2.8 ± 4.9 (n=25) 
-7.6 ± 13.9 (n=10) 
 
n.s. 
 
0.59 ± 0.708 (n=25) 
1.18 ± 2.36 (n=10) 
 
n.s. 
medical history of CD4 cells**
< 5 % 
> 5 % 
 
-6.7 ± 13.7 (n=13) 
-5.3 ± 9.6 (n=22) 
 
n.s. 
 
0.944 ± 1.062 (n=13) 
1.18 ± 1.18 (n=22) 
 
n.s. 
sex 
male  
female 
 
-5.1 ± 7.2 (n=19) 
-7.6 ± 16.4 (n=16) 
 
n.s. 
 
1.18 ± 1.298 (n=19) 
0.826 ± 1.416 (n=16) 
 
n.s. 
age 
< 5 years 
> 5 years 
 
-3.0 ± 3.4 (n= 6) 
-6.9 ± 13.2 (n=29) 
 
n.s. 
 
0.354 ± 0.59 (n=6) 
1.18 ± 1.416 (n=19) 
 
0.05 
reason for interruption 
inefficiency 
others 
 
-8.7 ± 15.2 (n=17) 
-3.8 ± 8.2 (n=18) 
 
n.s. 
 
0.944 ± 1.534 (n=17) 
1.062 ± 1.18 (n=18) 
 
n.s. 
n.s.= not significant (p > 0.05) 
* A viral load > 5 log10 copies/ml while receiving HAART was defined as “a medical history of a severe increase of viral load”. 
** A CD4 cell count < 5 % while receiving HAART was defined as “a medical history of severe immunodeficiency”. 
 
5. Genotypic resistance during treatment interruption 
In addition to plasma HIV RNA and CD4 cell count, the changes in genotypic drug resistance patterns 
were investigated. Patients were tested for HIV resistance before and after treatment interruption by stan-
dard methods. Those patients to whom therapy was reintroduced, were tested again before they started a 
new drug regimen, to analyse, which molecules were still active and could therefore be used for further 
treatment. The impact of treatment interruption on the resistance profile was assessed in all cases in which 
a second genotypic analysis was available during or at the end of the interruption period before antiretro-
viral treatment was reintroduced. In the first plasma sample of all patients before treatment interruption, 
27 of 35 children showed major mutations in the reverse transcriptase gene (RT gene). In 30 cases out of 
35 children major mutations of the protease gene were found in the first test. A second test was done for 
ten children, nine of whom were in the middle of a treatment interruption, whereas one child restarted 
therapy before the second test took place. Among these ten children however, a general reversion of ma-
jor mutations in the RT gene occurred in seven patients while the other three showed no change in the 
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mutation pattern at all. By regarding the seven children who experienced a reversion of resistant virus 
mutants, we noticed a complete reversion of all mutations in the RT gene in three children. In one child 
three of the original seven mutations were detected, in another child one of the three that were detected in 
the first test. The remaining two children showed only one major mutation of the RT gene less compared 
to the first test of genotypic resistance. 
Concerning the protease gene, three of the ten children in question showed at least one or two major 
mutations less throughout the period of treatment interruption. In one child, however, only one of origi-
nally seven major mutations was detected after five months of treatment interruption. It is interesting to 
see, that the same child has had nine major mutations of the RT gene in the first test, which were no 
longer detectable in the second test. Five children showed no reversion at all in the protease gene and in 
one child an additional major mutation was observed in the second test, which had not been detected be-
fore treatment interruption. Twelve out of 35 children had stopped antiretroviral therapy because of mul-
tiresistance development, four of them are documented to have less major mutations, one of them had 
completely changed back to the wild type virus. The results show, that a shift to drug-sensitive virus may 
also occur in HIV-infected children in the absence of antiretroviral drugs. 
 
6. Restarting therapy 
In 14 children (40 %) treatment was reintroduced. Reinstitution of antiretroviral therapy was associa-
ted with a prompt reduction in plasma viral load and an increase of CD4 cells within one month in all 
patients who resumed treatment. The 14 children who restarted therapy were seven boys and seven girls 
with an average age of 11.8 ± 4.8 years and a median age of 12 years [4.3;17.9].  
In ten of the 14 cases therapy was restarted because of an important increase of viral load after treat-
ment interruption (above 5 log10 copies/ml) or a severe decrease of CD4 cells (below 15 %). In two cases 
therapy was restarted because of clinical events such as a LIP (n=1) and a thrombopenia followed by fre-
quent episodes of epistaxis (n=1). Less severe clinical symptoms such as skin allergies (n=3) were hardly 
decisive for treatment reintroduction, except where they appeared in line with immunological events. In 
two cases the child or the child’s care giver elected to resume therapy. When a restart of antiretroviral the-
rapy was decided, the genotype of resistance was tested for all molecules the child had been taking so far. 
  
7. Treatment combinations used for reintroduction of therapy 
The most common therapy for those restarting antiretroviral treatment was a combination of two 
NRTIs and one NNRTI, which was prescribed to five of the 14 children. Three children restarted with a 
treatment consisting of two NRTIs and nelfinavir (PI), while a regimen including two PIs was prescribed 
three times. The other three children took various combinations, all consisting of one NNRTI in addition 
to PIs or NRTIs. 
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8. Development of immunological effects after reintroduction of therapy 
After reintroduction of antiretroviral therapy, plasma HIV RNA decreased to levels of 2 or 
3 log10 copies/ml within one month and undetectable levels of viral replication were finally reached in all 
children after approximately six months. An increase of CD4 cells of at least 2 % were noted in all chil-
dren in the first month after restarting therapy. After six months most children had reached a level of at 
least 15 % of CD4 cells. The clinical symptoms, which had appeared in some children in the absence of 
antiretroviral therapy regressed quickly within the first two months and no sequels were noted. 
 
9. Case reports 
In order to describe the three different types of response to the cessation of antiretroviral treatment, we 
present three case reports. 
9.1 Continual steady state for more than one year after treatment interruption 
The patient was born in 1986, having acquired HIV perinatally. At the age of seven months antiretro-
viral therapy was initiated with a zidovudine monotherapy after a series of infections of the respiratory 
tract. Due to a haematological intolerance to zidovudine she received a dual therapy of stavudine and 
lamivudine. At the age of ten she suffered from a serious LIP, so that a combination triple therapy became 
necessary (lamivudine, stavudine, indinavir). Triple therapy was changed twice because of incompatibil-
ity before it was stopped completely for reasons of a still existing pruritus under stavudine, abacavir and 
nelfinavir. The patient was categorized B3, antiretroviral treatment had been given for 12 years and two 
months. The lowest CD4 T-cell count had been 4 % (under bitherapy) and the highest plasma HIV RNA 
detected was 3 log10 copies/ml (under triple therapy). On the day of treatment interruption she had a CD4 
T-cell count of 17 % and a viral load of < 1.3 log10 copies/ml. There were no mutations on the RT gene 
nor on the protease gene. 
Plasma HIV RNA increased immediately after treatment interruption to 3.1 log10 copies/ml, while the 
CD4 T-cell count fell to 15 %. Three months later, viral load had reached a steady level of about 3.7 log10 
copies/ml, where it remained over the years with slight moderations, mainly ranging between 3.5 log10 
and 4.1 log10 copies/ml. CD4 cells rose up to 21.5 % after five months of treatment interruption and re-
mained at a steady level of about 19 %. In 15 months of treatment interruption, the patient developed no 
dangerous decrease of CD4 cells, but remained in a steady immunological state until the time of study 
end in December 2000 without further therapy. 
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Table 10: Continual steady state after treatment interruption 
date 
 
05.07. 
1999 
31.08. 
1999 
10.11. 
1999 
29.12. 
1999 
08.03. 
2000 
07.06. 
2000 
01.08. 
2000 
29.08. 
2000 
31.10. 
2000 
03.01. 
2001 
treatment on on off off off off off off off off 
viral load 
in RNA 
copies/ml  
150 < 20 
 
1400 
 
5300 
 
4800 
 
3300 
 
12000 
 
5900 
 
7200 
 
5500 
 
viral load 
in log10 * 
2.2 < 1.3 3.1 3.7 3.7 3.5 4.1 3.8 3.9 3.7 
CD4 
cells/µl in 
absolute 
numbers 
516    379 343 425 340 331  400 
CD4 cells 
in % 
 
18.9  17 15  15  21.5  18.6  19.4  19.9  19.9  17.5  
* method used: Amplicor HIV monitor (Roche) 
 
9.2 Immunological effects alternate without reaching a steady state 
The patient, born in 1994, interrupted therapy for reasons of inefficiency of therapy. Antiretroviral 
treatment had been started postnatally with a monotherapy of lamivudine to which zidovudine was added 
a month later. Finally she received a monotherapy of zidovudine, which was stopped completely after two 
years since a zidovudine monotherapy did not seem useful. For two years she stayed asymptomatic with-
out therapy, with a CD4 cell count of 34 % and a largely ranging viral load. A combination therapy of 
two NRTIs and one PI was restarted because of a buccal mycosis. In 1999, the plasma HIV RNA rose to a 
peak level of > 4 log10 copies/ml, demonstrating the inefficiency of her current drug regimen.  
Eventually, antiretroviral treatment was stopped two months later. At that time, the viral load was 
3.1 log10 copies/ml and the CD4 cell count was 32.5 %. She was categorised A1. The lowest CD4 cell 
count ever detected was 30 % and the highest plasma viremia was > 4 log10 copies/ml. Immunological 
parameters tested after four months of treatment interruption showed a decrease of CD4 cell count to 
28.6 % and an increased viral load of 5.7 log10 copies/ml. 
The CD4 cell count sank to 28.6 % after treatment interruption and the viral load varied between 
5.7 log10 and 3.7 log10 copies/ml. The final CD4 cell count at study end was 33.3 %, which was higher 
than during antiretroviral therapy. The plasma HIV RNA was 4.5 log10 copies/ml. The patient stayed as-
ymptomatic until study end 15 months after treatment interruption. 
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Table 11: Immunological effects alternate without reaching a steady state 
date 13.07.1999 22.09.1999 25.01.2000 05.04.2000 15.11.2000 
treatment on on off off off 
viral load in 
RNA copies/ml 
>10000  
 
1200  
 
51730 4900  
 
53000  
 
viral load in 
log10 * 
> 4 3.1 5.7 3.7 4.5 
CD4 cells/µl in 
absolute num-
bers 
503 521 353 330 427 
CD4 cells in % 33.1  32.5 28.6  25  33.3  
* method used: Amplicor HIV monitor (Roche) 
 
9.3 Prompt relapse of high HIV RNA levels requiring early restart of therapy  
After a perinatal HIV infection in 1992, this patient developed a buccal mycosis and started a zi-
dovudine monotherapy at the age of one year. Didanosine was added in 1996. After developing a severe 
neutropeny in 1997, therapy was changed to a triple combination therapy. But the neutropeny continued 
and the child showed great difficulty in tolerating nelfinavir, so that in regard of the low CD4 count and a 
high viral load, therapy was finally changed into another triple combination regimen (lamivudine, sta-
vudine, amprenavir). The viral load continued rising to peak levels of more than 5 log10 copies/ml, while 
the CD4 cell count stayed under 10 %. High plasma HIV RNA had been common in the medical history 
of this patient, the highest being > 6 log10 copies/ml, the lowest CD4 T-cell count was 2 %. 
Because of the many changes of antiretroviral treatment combinations and only minor success in the 
suppression of plasma HIV RNA, a treatment interruption was decided. On the day therapy was stopped 
the detected viral load was 5.1 log10 copies/ml, the CD4 T-cell count 11 %.  
Two months after discontinuing antiretroviral treatment plasma HIV RNA had risen to 6 log10 cop-
ies/ml and CD4 cells decreased to 4 %, in addition, erythema and pruritus had developed. Subsequently, 
antiretroviral therapy was restarted three months after the initial treatment interruption. After restarting 
therapy, plasma viral loads went down to less than 2 log10 copies/ml within one year and CD4 cell levels 
rose to 19 %. The child stopped her treatment again 18 months after the first interruption, because of dif-
ficulties in taking amprenavir and immediately experienced a viral load of > 6 log10 copies/ml while the 
number of CD4 cells sank to 8 %. Treatment had been stopped for two different reasons: firstly as a 
therapeutical strategy due to an insufficient treatment, and secondly due to a personal dislike to the regi-
men after a long period of a steady and asymptomatic state of health. Both immunological reactions were 
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similar. No sequelae were detected after reinitiation of therapy, even though the patient had a history of 
severe plasma viremia and immunodeficiency. It is noteworthy, that plasma HIV RNA fell clearly below 
the level detected before therapy had been interrupted for the first time. 
 
Table 12: Prompt relapse of high VL levels and low CD4 cell counts after treatment interruption 
date 02.02.1999 09.03.1999 11.05.1999 29.06.1999 13.07.1999 11.08.1999 14.09.1999 
treatment on on off off on on on 
viral load in RNA 
copies/ml 
358000 
 
130000  
 
858000  
 
545800  
 
1032  
 
731  
 
< 350  
 
viral load in log10 * 5.55 5.11 5.93 5.74 3.01 2.86 < 2.54 
CD4 cells/µl in 
absolute numbers 
not done 166 16 39 not done not done 97 
CD4 cells in %  11  4.1  3    4.3  
* method used: Amplicor HIV monitor (Roche) 
 
date 16.11.1999 18.01.2000 21.03.2000 13.06.2000 23.08.2000 24.10.2000 28.12.2000 
treatment on on on on on on off 
viral load in RNA 
copies/ml 
< 200  
 
< 220  
 
< 20  
 
< 400  
 
<400  
 
<400  
 
>1000000 
 
viral load in log10 * < 2.3 < 2.3 < 1.3 < 2 < 2 < 2 > 6 
CD4 cells/µl in 
absolute numbers 
181 256 not done 365 462 574 not done 
CD4 cells in % 7.4 16.7   14.9  17.6  18.7  8  
* method used: Amplicor HIV monitor (Roche) 
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IV. DISCUSSION 
We present the results of a retrospective study dealing with the interruption of antiretroviral therapy in 
HIV-1 infected children. It is the first paediatric study about treatment interruption to date and was loca-
ted in the Hôpital Necker-Enfants Malades in Paris, France. 
In this study we collected first information on treatment interruption in HIV-infected children to find 
out, whether it could be feasible. 60 % of the children in our study group (n=21) remained without ther-
apy for a prolonged period of time, thus reducing the risk of toxicity and the development of resistant 
virus strains. Even though 14 children restarted antiretroviral treatment, a general reduction of time on 
antiretroviral therapy could be achieved in all children. The results show a viral rebound in all patients 
within the first few weeks of treatment interruption. Certain subgroups however showed tendencies to-
wards a less significant loss of CD4 cells and a less severe increase of viremia during the time of treat-
ment interruption. In general we found a trend, that male children lost less CD4 cells and had a slightly 
less increase of HIV RNA copies during treatment interruption than female patients. Children under five 
years of age lost less CD4 cells and gained less HIV RNA copies than children above that age. Patients 
with a medical history of good immune responses and low HIV plasma viremia lost less CD4 cells and 
gained less HIV RNA copies than children with a severe medical history. In contrast, children who 
stopped therapy due to an insufficient treatment were seen to loose more CD4 cells and gain more HIV 
RNA copies than those, who had stopped therapy for other reasons (toxicity/inconvenience). Due to a 
shortage of information on treatment interruption in HIV-infected children, the results we present can 
only be compared to those of adult studies. 
According to the Swiss HIV Cohort Study in adults, occasional treatment interruptions of less than 
three months neither worsen nor improve disease outcome on an average term (three to four years). The 
results suggest that interruptions might be non-risky, particularly when viremia is low and CD4 cell count 
is high, but they still require confirmation [97]. Hirschel reported from the Swiss-Spanish Intermittent 
Treatment Trial (SSITT), that a substantial minority of patients taking combination therapy can be safely 
managed without drugs for at least several months. He also noted, that the best results came from the rare 
patients who started combination therapy during primary HIV infection [48]. In the meantime multiple 
studies investigated the different outcomes of treatment interruption in adults [100,99,19,73,24]. These 
trials were performed for different reasons (see I.1.6). A number of clinical trials using highly diverse 
protocols of STI have been conducted in patients who have initiated their first highly active antiretroviral 
treatment either during primary [91] or during chronic [36,85,86,33] HIV infection. Protocols used in STI 
studies usually vary widely with regard to the number and the duration of STI. However, their results are 
often similar to ours concerning the fact that viral rebound occurs in principally all patients shortly after 
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treatment interruption and that certain patients are more likely to profit from treatment interruptions than 
others. 
 
1. Random treatment interruption 
There are few reports on “random withdrawal” of antiretroviral therapy in patients who did not un-
dergo a scheduled program for treatment interruption. One report from the 9th Conference on Retrovi-
ruses and Opportunistic Infections (CROI) in Seattle in February 2002 [56] points out, that interruption of 
antiretroviral therapy can only be done in a strategically scheduled interruption. A European study of 
more than 3,600 HIV-infected patients reports that, of the 16 % who interrupted their therapy for other 
reasons, 51 % suffered an AIDS-defining illness or death during the interruption. The remaining 49 % 
restarted therapy [56].  
The EuroSIDA observational study by Lundgren et al. [66] reports data on the risk of developing a 
new AIDS-defining event (ADE) and/or death after interrupting or stopping antiretroviral therapy. Only 
patients who had been off therapy for at least three months were included in the analysis. After three 
months off therapy, the median reduction in CD4 cell count was 30 cells/mm3 and the increase in plasma 
HIV-1 RNA level was 1.0 log10 copies/ml. Overall, the risk of development of an ADE or death increased 
by more than fivefold, compared with the risk while receiving antiretroviral therapy. The risk was directly 
correlated to the CD4 cell count at the time of therapy discontinuation. Lundgren conceded that this ob-
servational study is limited by not being designed to evaluate structured treatment interruptions, and 
therefore may be biased by analysing patients with many different reasons for stopping therapy, possibly 
including some who were in the terminal stages of disease. The strong correlation between lower CD4 
cell count and much higher risk of developing an ADE/death is not surprising and has been noted in many 
other studies before; however, the magnitude of the increased risk (80 % among those who stopped ther-
apy with a CD4 cell count < 50 cells/mm3) is noteworthy. In any case, the risk of therapy interruption in 
patients with decreased CD4 cell counts and development of ADE/death in this study is even higher than 
in similar reports by Veronica Miller [73] and Steven Deeks [19] and their colleagues when evaluating 
whether a treatment interruption results in a beneficial reversion of viral phenotype from drug-resistant to 
wild-type, and provides reason for pause when considering this strategy.  
Another European study came to a similar result concerning random interruption of antiretroviral ther-
apy and also reports that the risk to develop serious complications seemed particularly strong for those 
whose CD4 cell counts were already fairly low around 200 cells/mm3 [56].   
In our study, none of the 35 children, who interrupted antiretroviral therapy randomly, suffered from 
AIDS-defining illness or death during the interruption. According to Hirschel [48], this could be due to 
the fact, that all children had been treated during primary infection and therefore had better chances to 
maintain a safe immunological state without therapy for months. Regarding our results, random interrup-
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tion of antiretroviral treatment may not necessarily be dangerous for every patient, provided the patient is 
under regular medical observation. This would suggest, that there are possibly more options for treatment 
withdrawal, which need further investigation in children.  
 
2. Medical history before treatment interruption 
An observational cohort study at the Johns Hopkins University includes 101 patients who discontinued 
therapy with the intention of restarting based on laboratory or clinical parameters [87]. Using a baseline 
CD4 cell count of > 500 cells/mm3 as a referent, those with a CD4 cell count < 200 cells/mm3 were seven 
times more likely to resume therapy. Patients with high viral load set points and low CD4 cell count at the 
time of their original start of therapy were 2.9 times more likely to resume therapy [87]. The study refers 
to the pulse therapy strategy, in which the goal is to keep the CD4 cell count above a predetermined 
threshold using cycles of therapy followed by prolonged interruptions. Presumably those patients with 
relatively low viral load set points and good CD4 cell count responses to HAART will be able to discon-
tinue therapy safely for a longer period of time. Apparently the original state of the immune system plays 
an important role for the outcome of treatment interruption not only in adults but also in children as we 
can conclude from our study. Similar to the adult studies named above, children with low CD4 cell counts 
(CD4 cells < 5 %) and high viral load set points (> 5 log10 copies/ml) lost more CD4 cells and gained 
more HIV RNA copies during treatment interruption than others. In addition, they were more likely to 
resume therapy (ten of the 14 children who restarted antiretroviral therapy were children with a medical 
history of low CD4 cells and high viral loads).  
 
3. Early start versus late start of antiretroviral therapy 
A debate continues over whether to start therapy as soon as possible after infection or at a later point. 
Arguments for very early intervention are, that therapy is able to stop the virus from destroying as much 
of the immune system as it might if left unchecked. Later intervention would delay the development of 
side effects and toxicities [56]. 
Most children of our study group received antiretroviral therapy shortly after birth, so that they are 
candidates for early intervention strategies. According to a study by Walker and colleagues, early inter-
vention during seroconversion predisposes the patient to good results during and after treatment inter-
ruption [99]. Patients of Walker’s study were diagnosed and treated before Western blot seroconversion 
and eight of 14 patients maintained viral loads < 5000 copies/ml after at least one STI. Similar successful 
results could hardly be seen in other studies, which is probably because treatment was not initiated as 
early as in Walker’s study. It is possible however, that children who have been treated since birth could 
benefit even more from antiretroviral treatment interruption than adults with chronic HIV infections. On 
the other hand, the immune system is not yet fully developed at the time of birth, which is another factor 
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to influence the results of treatment and treatment interruption. Controlled trials are necessary, in order to 
assess the effectiveness of treatment interruption after early onset of antiretroviral therapy. Unfortunately, 
only few patients are diagnosed during acute infection and controlled trials are therefore difficult to carry 
out in adults. 
Rosenberg and colleagues from the Massachusetts General Hospital have studied a group of acute in-
fected patients who underwent STIs in order to augment HIV-specific immune responses [91]. HIV RNA 
levels increased in all patients during the first STI within 17 days, but soon dropped in some patients be-
low 5,000 copies/ml. It is noteworthy that, compared to the first STI, the majority of patients experienced 
a much slower rebound in HIV RNA levels during the second STI that would require them to restart ther-
apy. This would account for the thesis, that immune response is broadening and is becoming stronger 
during treatment interruptions, which may indicate why the patients are able to control their virus. The 
role of STI in patients with primary infection appears promising, but the potential in chronically infected 
patients (infected with HIV for more than six months) is not very clear yet. According to Dybul [27], 
some studies do suggest that autoimmunisation can occur in a very small percentage of effectively treated 
chronically infected patients, but the benefit of autoimmunisation in these patients over more than one 
year off therapy is almost zero.  
 
4. Short and long cycles of STI 
Another study by Dybul et al. [24] reports that in a small cohort of patients with undetectable plasma 
viral loads after HAART, repeated cycles of one-week-on followed by one-week-off HAART did not lead 
to rebound of viral load during the drug-free period in any of the eight subjects investigated. This sched-
ule is thought to minimise the emergence of drug resistance during interruption or reinitiating phases, 
since viral rebound typically takes longer than seven days to occur. HIV replication did not resume within 
one week after treatment cessation, so that emergence of drug-resistant virus during this type of STI was 
deemed unlikely.  
A recent study from the Swiss HIV Cohort Study in a greater number of patients showed a different 
result however. The one-week-on-one-week-off schedule of the ongoing Staccato Study [2] showed a 
high failure rate and had to be terminated prematurely since 53% of the group were classified as virologi-
cal failure at the end of the week off therapy. These data are in conflict with what was previously reported 
by Dybul et al. and are therefore of great concern regarding this strategy. There exist a number of differ-
ences between these two studies though. Patients enrolled in the two studies were on different pre-study 
HAART regimens and this may present a major confounding factor. Moreover, 70% of the patients in the 
Dybul-study had a history of interleukin-2 therapy and a high CD4 cell count prior to starting STI [1].  
In STI studies using longer cycles (two-months-on/one-month-off), in which viral load is allowed to 
rebound, resistance to lamivudine (M184 V/I) and NNRTIs has typically emerged in patients treated with 
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regimens containing those agents [28]. One STI study that used longer cycles is for example the study by 
Fischer et al. [29]. It includes 14 chronically HIV infected patients who are enrolled in the SSITT study 
(Swiss Spanish Intermittent Treatment Trial) and presents results after examining the viral rebound in 
two-week STI periods. They concluded, that significant viral replication can be induced during one week 
STI, which may increase the risk of the development of drug resistance during long-term cycles.  
However, there are also some differences between the studies of Dybul et al. and Fischer et al., which 
could have led to different outcomes. These are again the use of different drugs and also different DNA 
assays or the use of immunomodulatory therapy before STI (Dybul et al. used interleukin-2). Fischer and 
colleagues have studied 14 patients, Dybul observed ten patients, two of which left the study before study 
end for personal reasons. In general, assessing small numbers of patients can lead to different outcomes 
because of unrecognised confounding factors.  
In his latest study, Dybul et al. also evaluated the effect of long-cycle structured intermittent therapy 
(SIT; four weeks without HAART followed by eight weeks with HAART) on serum lipid levels, hepatic 
enzymes, high-sensitivity C-reactive protein (hsCRP), plasma HIV RNA levels, CD4 and CD8 T-cell 
counts, markers of cellular immune activation, and CD4 HIV specific immune response [26]. They dem-
onstrated that in contrast to the short-cycle study [24], long intermittent therapy with HAART did not 
result in a diminution of toxicities associated with administration of HAART. In addition, it did not en-
hance or decrease measurable immunologic parameters after 48 weeks of long-cycle SIT versus continu-
ous HAART. However, because periodic reductions in serum total cholesterol and triglyceride levels 
were observed during the without-HAART intervals, there may be a long-term advantage to intermittent 
decrease in certain markers of toxicity [26].  
The SSITT by Hirschel et al. used a two-weeks-on/eight-weeks-off schedule in 133 chronically in-
fected patients who had been successfully treated with antiretroviral therapy [48]. An improved HIV-
specific CD8 response was observed with treatment interruption, but did not correlate with virological 
response. After one year of intermittent therapy, few patients maintained low-level viremia during treat-
ment interruption, and only 6 % remained off therapy at week 96, which was the ultimate goal of the trial. 
But since this was not a controlled trial, it is difficult to attribute these successes to treatment interruption 
itself. Hirschel pointed out, that the SSITT suggests that STI will rarely be sufficient to attain the goal of 
low viremia without antiretroviral therapy and that the results of his study essentially refute the idea that 
autoimmunity might be achieved through random interruption of therapy. 
 
5. Resistance after treatment interruption 
All children in our study group were tested for genotypic resistance before they interrupted antiretrovi-
ral therapy. Ten of the 35 children underwent a second test while being off therapy, seven of which 
showed a reversion of major mutations and one child showed a complete shift to wild-type virus. Specific 
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studies are needed to find out in what way treatment interruption can influence multidrug resistance in 
children and whether there are any relations to CD4 cell count and viral load, as has been observed in 
some adult studies. 
Miller’s team for example observed a complete shift to wild-type virus in 28 of 45 patients during 
treatment interruption [73]. There was an average viral load increase of 0.7 log10 copies/ml during the 
patients’ STIs. The median CD4 cell count was 49 cells/mm3 by the end of the treatment interruption, 
reflecting a profound median drop of 89 cells/mm3. The decline in CD4 cells was significantly greater 
among those who experienced a shift to wild-type virus compared with other patients who did not (-122 
versus -25 cells/mm3).  
That shows, that a shift to drug-sensitive virus does occur, but drug-resistant virus still persists. In con-
trast, patients staying on a failing regimen may experience a much slower decline in CD4 cell count, or 
may even remain stable, presumably because their predominant virus has mutations decreasing viral rep-
lication [35]. 
 
6. Summary 
At present no other paediatric studies on antiretroviral treatment interruption are available. There are 
certain similarities between the responses to treatment interruption of adults and children. Even though 
repeated treatment interruptions do not result in permanent low viremia without antiretroviral therapy 
[48], treatment interruptions may still be viable in patients (especially children) treated during primary 
infection. Frequent treatment interruptions as a form of autovaccination to boost HIV-specific immune 
responses are unlikely to be proven effective in chronic HIV infection. Adults and children with good im-
mune responses before treatment interruption (high CD4 cell counts and low viral load setpoints) are pro-
bably able to discontinue therapy for a longer period of time and this may effectively reduce toxicity and 
save therapeutical costs. When treatment is interrupted in patients who fail HAART and who have drug-
resistant HIV, the drug-sensitive wild-type may replace the resistant virus strain but it is very unlikely that 
this confers clinical benefit. It remains to be seen, whether these results are transferable to patients outside 
of clinical trials, so that large studies are needed to further compare the risks and benefits of treatment in-
terruption. 
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V. CONCLUSION 
Combination therapy is still the standard for HIV-infected patients, who are symptomatic or who reach 
certain thresholds for CD4 cells and/or viral load. Unfortunately, long-term therapy is hampered by chro-
nic toxicity, emergence of drug resistance and a sometimes low adherence to complicated regimens. Stu-
dies in adults demonstrate at least partial beneficial effects of structured treatment interruption (STI) as a 
strategy to reduce the limitations of HAART. 
At present, there are no data concerning treatment interruption in children. Our study shows, that 
treatment interruption in HIV-infected children is feasible in some patients. Of the 35 children who had 
interrupted treatment 21 children managed to stay without further therapy for a prolonged period of time, 
in some cases even for three years. Even though we noticed a viral rebound in all patients within the first 
few weeks of treatment interruption, there were different profiles of immunological reaction. Especially 
children, who had good immune responses before treatment interruption and who had stopped therapy at 
an early age before running the risk of virological treatment failure, showed the best results as was also 
seen in adult studies. On the contrary, patients who had stopped therapy because of virological treatment 
failure had a greater loss of CD4 cells and showed an important increase of viral load in the time off ther-
apy so that a prolonged treatment interruption was not advisable for them. But even though therapy had to 
be restarted for 14 patients, a general reduction of time on drug therapy could be achieved. 
The idea of treatment interruption is based on certain results in adult studies, which show, that in some 
patients successive interruptions might increase the duration of immunologic control of viral replication 
while off therapy. Therefore, the need for antiretroviral treatment may progressively be reduced. Also, the 
patient’s immune system can occasionally be effectively boosted at least to some amount after the discon-
tinuation of therapy. In the context of a failing antiretroviral therapy and emergence of genotypic resis-
tance STI may re-establish a dominant population of drug sensitive virus. However, current evidence 
shows that such goals may be unrealistic except in patients treated during primary infection. Therefore, it 
is important to diagnose the HIV infection in patients in the acute phase of the infection. In chronically 
infected patients a beneficial effect of STI on viremia control was more difficult to demonstrate since the 
virus rebounded in basically all patients.  
Similar to adult studies, our data suggest, that a significant proportion of HIV-infected children can be 
safely taken off therapy for a prolonged period of time to reduce toxicity and costs, especially those with 
low viral load and good CD4 cell counts before treatment interruption. But further investigation of treat-
ment interruption in paediatric patients is necessary until proper advice can be given. What is needed are 
prospective studies to evaluate the advantages and risks of new treatment strategies in HIV-infected chil-
dren.  
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ABSTRACT 
 
This study deals with the effects of treatment withdrawal in HIV-infected children. In a retrospective 
survey 35 HIV-infected children who were under medical treatment in the Hôpital Necker-Enfants 
Malades in Paris, France, were observed concerning their discontinuation of antiretroviral therapy after 
months or years of receiving treatment. All children had acquired HIV infection through vertical trans-
mission and received antiretroviral therapy for at least ten months before interrupting therapy for different 
reasons between 1996 and 2000 (insufficiency, toxicity, inconvenience). 
The study group consisted of 16 girls and 19 boys with an average age of 10.4 ± 4.9 years at the time 
treatment was stopped. The average time of observation after treatment interruption was 325 ± 294 days. 
Plasma HIV RNA was tested approximately every three months using an RNA polymerase chain reaction 
test. The CD4 cell count was regularly checked approximately at the same time as the viral load and 
measured by flow cytometry. To estimate the presence of major mutations in the HIV reverse transcrip-
tase and protease genes, genotypic resistance was tested before treatment interruption, in the absence of 
antiretroviral treatment and in the case of a restart of therapy, when a new combination of efficient agents 
had to be defined. Based on the assumption that the course of HIV RNA viral load and CD4 cell count 
depended on certain factors, distinctions were made between the medical history of viral load and CD4 
cell count, age, sex and reason for treatment interruption. The changes of CD4 cell count and viral loads 
were then analysed to calculate the percentage of lost CD4 cells and the increase of viral load per day of 
treatment interruption.  
By the time the study was finished in December 2000, 21 children were still without any further anti-
retroviral therapy whereas 14 children had to restart therapy. Even though we noticed a viral rebound in 
all patients within the first few weeks of treatment interruption, there were different profiles of immuno-
logical reaction. Especially children, who had good immune responses before treatment interruption and 
who had stopped therapy at an early age (under 5 years) before running the risk of virological treatment 
failure, showed the best results. On the contrary, patients who had stopped therapy because of virological 
treatment failure had a greater loss of CD4 cells and showed an important increase of viral load in the 
time off therapy so that a prolonged treatment interruption was not advisable for them. But even though 
therapy had to be restarted for 14 patients, a general reduction of time on drug therapy could be achieved. 
Similar to adult studies, our data suggest, that a significant proportion of HIV-infected children can be 
safely taken off therapy for a prolonged period of time in order to reduce toxicity and costs. 
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ZUSAMMENFASSUNG 
 
Die vorliegende Studie befasst sich mit den Folgen des Therapieabbruchs bei HIV-infizierten Kindern. 
35 Kinder, die sich aufgrund ihrer HIV Infektion im Hôpital Necker-Enfants Malades in Paris in medizi-
nischer Behandlung befanden, wurden retrospektiv hinsichtlich der Unterbrechung ihrer antiretroviralen 
Therapie untersucht. Alle Kinder waren durch vertikale Transmission infiziert worden und hatten minde-
stens zehn Monate lang eine antiretrovirale Medikation erhalten, bevor diese zwischen 1996 und 2000 aus 
verschiedenen Gründen abgesetzt wurde (Ineffizienz der Therapie, Toxizität, persönliche Entscheidung).  
Die Studiengruppe bestand aus 16 Mädchen und 19 Jungen in einem durchschnittlichen Alter von 10,4 
Jahren ± 4,9 zum Zeitpunkt des Therapieabbruchs. Der Beobachtungszeitraum nach dem Therapieab-
bruch betrug im Durchschnitt 325 ± 294 Tage. Der Plasma HIV RNA Spiegel wurde in Abständen von 
drei Monaten mittels eines RNA-PCR-Tests (polymerase chain reaction) ermittelt. Gleichzeitig wurde die 
Anzahl der CD4 Zellen mit Hilfe von Flowzytometrie untersucht. Um das Auftreten von Virusmutationen 
des Protease- bzw. des HIV Reverse Transkriptase-Gens festzustellen, wurde der Genotyp der Resisten-
zen vor dem Therapieabbruch, in der Therapiepause und im Falle einer Wiederaufnahme der Therapie 
untersucht, letzteres, um eine neue Kombination von wirksamen Medikamenten festlegen zu können. In 
der Annahme, dass der Verlauf von Viruslast und Anzahl der CD4 Zellen in Abhängigkeit zu bestimmten 
Faktoren steht, wurden folgende Kategorien unterschieden: bisheriger Verlauf der Viruslast und der An-
zahl der CD4 Zellen, Alter, Geschlecht und Grund für den Therapieabbruch. Veränderungen in der An-
zahl der CD4 Zellen und der Viruslast wurden in der Folge analysiert, um den Prozentsatz des Verlustes 
von CD4 Zellen sowie den Anstieg der Viruslast pro Tag der Therapiepause zu berechnen.  
Zum Zeitpunkt des Studienendes im Dezember 2000 waren 21 Kinder noch immer ohne antiretrovira-
le Therapie, während 14 Kinder die Therapie wieder aufnehmen mussten. Bei allen 35 Patienten war in-
nerhalb der ersten Wochen nach Therapieabbruch ein prompter Wiederanstieg der Viruslast zu verzeich-
nen, es ergaben sich jedoch deutliche Unterschiede im Hinblick auf die immunologische Reaktion. Die 
besten Ergebnisse konnten bei den Kindern festgestellt werden, die bereits vor dem Therapieabbruch gute 
Immunantworten gezeigt, beziehungsweise in einem frühen Alter (unter 5 Jahren) die Therapie abgesetzt 
hatten. Im Gegensatz dazu war bei Kindern, die ihre Therapie wegen Ineffizienz unterbrochen hatten ein 
größerer Verlust von CD4 Zellen und ein massiverer Viruslastanstieg zu beobachten. Trotz der Wieder-
aufnahme der antiretroviralen Therapie bei 14 Kindern konnte eine generelle Reduktion der Therapiezeit 
erreicht werden. Die Resultate belegen, ähnlich wie aus Studien bei Erwachsenen bekannt, dass eine ge-
wisse Anzahl HIV-infizierter Kinder ohne größeres Risiko die antiretrovirale Therapie unterbrechen und 
auf diese Weise sowohl toxische Nebenwirkungen als auch Kosten gering halten kann.  
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